These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16432140)

  • 41. Etanercept treatment in myasthenia gravis.
    Rowin J
    Ann N Y Acad Sci; 2008; 1132():300-4. PubMed ID: 18567881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J; McHugh N; Singh A; Wajdula JS; Sato R
    Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P; Del Giglio M; Cotena C; Girolomoni G
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of etanercept in the treatment of dermatomyositis: a case series.
    Iannone F; Scioscia C; Falappone PC; Covelli M; Lapadula G
    J Rheumatol; 2006 Sep; 33(9):1802-4. PubMed ID: 16960940
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
    Lovell DJ; Reiff A; Jones OY; Schneider R; Nocton J; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore JB; White B; Giannini EH;
    Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
    Bathon JM; Fleischmann RM; Van der Heijde D; Tesser JR; Peloso PM; Chon Y; White B
    J Rheumatol; 2006 Feb; 33(2):234-43. PubMed ID: 16465653
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis.
    Muscle Study Group
    Neurology; 2004 Aug; 63(4):718-20. PubMed ID: 15326251
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, pilot trial of etanercept in dermatomyositis.
    Muscle Study Group
    Ann Neurol; 2011 Sep; 70(3):427-36. PubMed ID: 21688301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study.
    Kosmidis ML; Alexopoulos H; Tzioufas AG; Dalakas MC
    J Neurol Sci; 2013 Nov; 334(1-2):123-5. PubMed ID: 23998706
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognosis and prognostic factors in sporadic inclusion body myositis.
    Lindberg C; Oldfors A
    Acta Neurol Scand; 2012 May; 125(5):353-8. PubMed ID: 21916852
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis.
    Muscle Study Group
    Neurology; 2001 Nov; 57(9):1566-70. PubMed ID: 11706093
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pilot randomized trial of oxandrolone in inclusion body myositis.
    Rutkove SB; Parker RA; Nardin RA; Connolly CE; Felice KJ; Raynor EM
    Neurology; 2002 Apr; 58(7):1081-7. PubMed ID: 11940697
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-dose vitamin C therapy for inclusion body myositis.
    Yamada T; Minohara M; Imaiso Y; Sakae N; Hara H; Tanaka K; Yamamoto T; Taniwaki T; Furuya H; Kira J
    Fukuoka Igaku Zasshi; 2001 Apr; 92(4):99-104. PubMed ID: 11411094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis.
    Sancricca C; Mora M; Ricci E; Tonali PA; Mantegazza R; Mirabella M
    Neurol Sci; 2011 Oct; 32(5):841-7. PubMed ID: 21695654
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploring hand and upper limb function in patients with inclusion body myositis (IBM).
    Hunn S; Alfano L; Seiffert M; Weihl CC
    Neuromuscul Disord; 2023 Aug; 33(8):643-650. PubMed ID: 37451936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term strength and functional status in inclusion body myositis and identification of trajectory subgroups.
    Oldroyd AGS; Lilleker JB; Williams J; Chinoy H; Miller JAL
    Muscle Nerve; 2020 Jul; 62(1):76-82. PubMed ID: 32134516
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Further observations on forearm flexor weakness in inclusion body myositis.
    Felice KJ; Relva GM; Conway SR
    Muscle Nerve; 1998 May; 21(5):659-61. PubMed ID: 9572250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.
    Badrising UA; Maat-Schieman ML; Ferrari MD; Zwinderman AH; Wessels JA; Breedveld FC; van Doorn PA; van Engelen BG; Hoogendijk JE; Höweler CJ; de Jager AE; Jennekens FG; Koehler PJ; de Visser M; Viddeleer A; Verschuuren JJ; Wintzen AR
    Ann Neurol; 2002 Mar; 51(3):369-72. PubMed ID: 11891832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A prospective natural history study of inclusion body myositis: implications for clinical trials.
    Rose MR; McDermott MP; Thornton CA; Palenski C; Martens WB; Griggs RC
    Neurology; 2001 Aug; 57(3):548-50. PubMed ID: 11502935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.